These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23789365)

  • 1. [Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy].
    Volkov AA; Petrichko MI; Budnik NV; Dukhin AR
    Urologiia; 2013; (2):56, 58-9. PubMed ID: 23789365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correction of erectile dysfunction in patients with benign prostate hyperplasia using daily administration of tadalafil 5 mg against the background of combined drug therapy].
    Volkov AA; Petrichko MI; Budnik NV
    Urologiia; 2013; (5):50-2, 54. PubMed ID: 24437241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction].
    Kamalov AA; Takhirzade AM
    Urologiia; 2018 Jul; (3):70-77. PubMed ID: 30035422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC; Rosenberg M; Kissel J; Wong DG
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
    Goldfischer E; Kowalczyk JJ; Clark WR; Brady E; Shane MA; Dgetluck N; Klise SR
    Urology; 2012 Apr; 79(4):875-82. PubMed ID: 22341603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
    Kamalov AA; Takhirzade AM
    Urologiia; 2017 Dec; (6):160-163. PubMed ID: 29376615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.
    Lee JY; Park SY; Jeong TY; Moon HS; Kim YT; Yoo TK; Choi HY; Park HY; Lee SW
    J Androl; 2012; 33(3):397-403. PubMed ID: 21868753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
    Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
    Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG; Kaminetsky JC; Auerbach SM; Montelongo RM; Elion-Mboussa A; Viktrup L
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Porst H; McVary KT; Montorsi F; Sutherland P; Elion-Mboussa A; Wolka AM; Viktrup L
    Eur Urol; 2009 Oct; 56(4):727-35. PubMed ID: 19409693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study.
    Maselli G; Bergamasco L; Silvestri V; Gualà L; Pace G; Vicentini C
    Int J Urol; 2011 Jul; 18(7):515-20. PubMed ID: 21592232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study.
    Lee JY; Cho SY; Oh CY; Ha US; Lee SH; Park SY; Moon HS; Lee SW
    Int J Impot Res; 2011; 23(6):249-56. PubMed ID: 21814227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
    Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
    Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.